/
Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter s life-threatening rare disease, pulmonary arterial hypertension ( PAH ), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs…
Margins and capital returns are both well above average: 46.89% operating margin, ROIC at 16.44%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 10.6%, still solid.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$3.17B
▲ +10.6% YoY
Net Income (TTM)
$1.29B
▲ +11.7% YoY
Op. Margin
45.29%
▼ -1.0pp YoY
ROIC
16.65%
▼ -0.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.02B
▼ -3.7% YoY
Op. Cash Flow (TTM)
$1.56B
▲ +17.6% YoY
Net Debt
-$2.15B
Net Cash Position
Cash & Equiv.
$2.15B
5Y CAGR: +16.5%
5Y CAGR: +8.4%
Continue Research